InsidersTradesSigma
Follow the TELA Bio, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, TELA Bio, Inc. has logged 15 reports. Market capitalisation: €31.8m. The latest transaction was reported on 17 July 2026 (Attribution). Among the most active insiders: Capper Joseph H. Every trade is openly available.
15
Insider Decl.
n/a
Thresholds
€3m
1 ops.
Buy Volume
n/a
n/a
Sell Volume
26Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,815 of 28,833 companies
22.3
score / 100
Value1
Quality44
FCF yld-98%
Earn yld-132%
EV/EBITDA·
ROE·
Gross mgn68%
Net mgn-48%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 July 2026
Declarations15 total
6,227 shares@ US$0.7850.014% mcap100.0% of flowCommon StockSEC:0001456817-26-000011:0
20,930 shares@ US$0.7850.047% mcap100.0% of flowCommon StockSEC:0001685640-26-000003:0
11,925 sharesCommon StockSEC:0001456817-26-000009:0
11,675 sharesCommon StockSEC:0001456817-26-000009:1
86,000 shares0Common StockSEC:0002012926-26-000004:0
37,000 shares0Common StockSEC:0001984584-26-000002:0
32,850 shares0Common StockSEC:0001899973-26-000002:0
57,000 shares0Common StockSEC:0001899089-26-000002:0
57,000 shares0Common StockSEC:0001591474-26-000002:0
176,000 shares0Common StockSEC:0001195881-26-000002:0
3,604,000 shares@ US$1.11100.0% of flowCommon Stock, par value $0.001 per shareSEC:0000908834-25-000358:0
Canonical exit: 15 Feb 2026 (T+90)
11,925 shares0Common StockSEC:0001685640-25-000006:0
11,925 shares0Common StockSEC:0002089250-25-000004:0
1,093 shares@ US$1.86100.0% of flowCommon StockSEC:0001062993-25-013584:0
7,950 shares0Common StockSEC:0001062993-25-010569:0
15 of 15 declarations
About TELA Bio, Inc.
TELA Bio, Inc. is a U.S.-based medical technology company listed on the NASDAQ market in the United States. The company focuses on innovative soft-tissue reconstruction solutions designed to support surgical repair and reconstruction while prioritizing preservation of the patient’s own anatomy. Headquartered in Malvern, Pennsylvania, TELA Bio is primarily commercial in the U.S. market, with a smaller international footprint. ([ir.telabio.com](https://ir.telabio.com/news-releases/news-release-details/tela-bio-reports-fourth-quarter-and-full-year-2025-financial/)) Founded in 2012, the company was built around a biomaterials platform for soft-tissue reconstruction. Its portfolio originally centered on abdominal wall reconstruction and hernia repair, and later expanded into plastic and reconstructive surgery. Key products include OviTex, used in soft-tissue reconstruction and hernia repair, and OviTex PRS, aimed at plastic and reconstructive surgery applications. TELA Bio has also secured FDA 510(k) clearances for product families such as Restella and for certain OviTex PRS configurations, which have supported broader commercial adoption. ([ir.telabio.com](https://ir.telabio.com/news-releases/news-release-details/tela-bio-announces-510k-clearance-ovitexr-prs-long-term)) From a competitive standpoint, TELA Bio is a specialized player rather than a large diversified medtech platform. Its differentiation comes from the combination of biomaterial design, clinical evidence, and a focused commercial model targeting hospital-based surgeons. In the highly competitive soft-tissue reconstruction market, the company is seeking share gains through product performance, expanded sizes/configurations, and deeper commercial penetration. At the same time, the business remains exposed to the usual medtech risks: reimbursement dynamics, clinical adoption, pricing pressure, the need for ongoing evidence generation, and sustained sales-force investment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm)) Recent developments point to growth momentum, but also to a business that is not yet profitable. In the second quarter of 2025, TELA Bio reported revenue of $20.2 million, up 26% year over year, with particularly strong growth in OviTex PRS. In March 2026, the company said it closed 2025 with its strongest quarterly revenue on record at $20.9 million in Q4 2025, while keeping operating expenses essentially flat for the year. In early 2026, management also announced a strategic board refresh aimed at accelerating growth and supporting the path to profitability. For investors, TELA Bio remains a niche medtech growth name on the NASDAQ, with attractive commercial potential but continuing execution and profitability risk. ([ir.telabio.com](https://ir.telabio.com/news-releases/news-release-details/tela-bio-reports-second-quarter-2025-financial-results))
